FDA seeks more data from Teva Pharm on Treanda
TEL AVIV Oct 23 (Reuters) - The U.S. Food and Drug Administration is seeking more data from Teva Pharmaceutical Industries regarding its request to expand the use of its chemotherapy drug Treanda for non-Hodgkin lymphoma.
Teva obtained Treanda through its acquisition of Cephalon last year and the drug generated $139 million in sales in the second quarter of 2012.
Teva is seeking to expand the use of Treanda as a first-line treatment of patients with indolent B cell non-Hodgkin lymphoma in combination with rituximab, an antibody used to treat non-Hodgkin lymphoma. The FDA requested additional data regarding progression free survival.
"Teva is currently evaluating all options to obtain the requested data," the company said in a statement on Tuesday.
Treanda is currently indicated as a secondary treatment for non-Hodgkin lymphoma. (Reporting by Tova Cohen)
- Man called Bitcoin's father denies ties, leads LA car chase
- Malaysia Airlines loses contact with plane carrying 239 people
- Ukraine standoff intensifies, Russia says sanctions will 'boomerang' |
- Florida mayor fights backyard gun ranges in 'Gunshine State'
- Apple loses bid for U.S. ban on Samsung smartphone sales